Rik J Verheijden
11PUBLICATIONS
21CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (11)
Sort by Publication Date:
|Nov 18, 2025
Blood and tissue correlates of steroid non-response in checkpoint inhibition-induced immune-related adverse events.Mick J M van Eijs, M Marlot van der Wal, Hedi-Britt Klotškova
|Sep 02, 2025
Anti-PD-1 treatment response is associated with the influx of circulating myeloid and T-cell subsets into the metastatic melanoma tumor microenvironment.S Van Dam, D Krijgsman, E Küçükköse
|Aug 07, 2024
Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials.Rik J Verheijden, Jolien S de Groot, Babs O Fabriek
|Jul 05, 2024
In vitro T cell responses to PD-1 blockade are reduced by IFN-α but do not predict therapy response in melanoma patients.Laura M Timmerman, Lobke C M Hensen, Mick J M van Eijs
|Nov 24, 2023
Physical activity and checkpoint inhibition: association with toxicity and survival.Rik J Verheijden, Anna Cabané Ballester, Karel C Smit
|Oct 04, 2023
Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition.Mick J M van Eijs, Rik J Verheijden, Stefanie A van der Wees
Pageof 2
Frequent Collaborators
11 joint publications
Karijn P M Suijkerbuijk
7 joint publications
Mick J M van Eijs
4 joint publications
Femke van Wijk
3 joint publications
Anne M May
2 joint publications
Hedi-Britt Klotškova
2 joint publications
M Marlot van der Wal
2 joint publications
Mark Schuiveling
2 joint publications
Babs O Fabriek
2 joint publications
Anne S R van Lindert
1 joint publications
O Kranenburg
